has with Google Cloud to leverage generative artificial intelligence (AI) to transform the discovery, development and marketing of drugs in the life sciences sector.
The collaboration will unite the AI technology of Google Cloud with Insmed鈥檚 capabilities in serious and rare ailments to reduce time and boost efficiency in the development and delivery of new drugs.
The partners will focus on the discovery, development and commercialisation of drugs and enabling functions.
Up to three initiatives in each field have been identified by the parties for completion up to March 2025, with further programmes to be included after that.
Leveraging Vertex AI Search, Insmed has created a generative AI search expertise with knowledge of its internal records and a distinct functionality that allows categorised access to external medical articles.
Insmed chair and CEO Will Lewis stated: 鈥淭his collaboration represents a multi-year commitment to bring about real change to the drug development process.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData鈥淩educing the timeline for drug development and enhancing the delivery of drugs to appropriate patients would represent a major breakthrough for the application of AI in the life sciences ecosystem.
鈥淕oogle Cloud is the clear partner of choice in this effort and we are thrilled to work together to pursue a future where groundbreaking therapies are developed with unprecedented speed and precision.”
Insmed focuses on developing treatments for serious and rare ailments with its first therapy for lung disease already approved in the US, Europe and Japan.
Its pipeline comprises investigational therapeutics for ailments such as neutrophil-mediated inflammatory diseases and rare pulmonary disorders.
